Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevenar in High Risk Children
NCT00581620Phase 4Completed
- Sponsor
- Pfizer
- Start
- Nov 2002
- Modality
- Split/Subunit Vaccines
01
Overview
Phase 4, open-label trial of pneumococcal 7-valent conjugate vaccine in pneumococcal infection (4 arms), sponsored by Pfizer. Primary endpoint: Immunogenicity of the heptavalent CRM197 pneumococcal conjugate at 4 months. Started Nov 2002; status: completed.
02
Drugs
pneumococcal 7-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00581620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00581620.